Related Experiment Video
Updated: Mar 27, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label,
Assaf Shelef1, Yoram Barak1, Uri Berger2
1Abarbanel Mental Health Center, Bat-Yam, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Background:
Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).
Objective:
To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
Methods:
Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
Results:
Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.
Conclusion:
Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.
Related Concept Videos
Alzheimer's Disease: Treatment
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Dementia
The progression of dementia is generally gradual....
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Pharmacodynamics in Geriatric Patients: Effects of Age
Drug Dosing: Geriatric Patients

